A purple and pink letter v on a white background.
September 15, 2021

Skin Care and Aesthetics for Darker Skin Tones

Beauty and skin care launches designed specifically for darker shades of skin have reached a fever pitch of late—and we love to see it. Celebrities like Rihanna, athletes like Naomi Osaka, and industry professionals like Pat McGrath have all launched successful brands that meet the demand of people of all skin tones. Th eir success demonstrates that there is a huge demographic eager to pursue their aesthetic goals. At the same time, it has revealed that there are still challenges present for medical aesthetic practitioners to address the unique needs of people with darker skin. Below, we explore the complexities of treating a broader spectrum of skin tones, and what new medical aesthetic technologies are doing to solve them.

Aesthetic Technology f or Darker Skin

Like beauty trends, the field of medical aesthetics is constantly evolving. In recent decades there has been mounting pressure for the cosmetic and aesthetic industries to cater to a wider range of skin tones. In answer, the latest modalities for aesthetic treatments have been designed with inclusivity in mind. While older medical aesthetic technologies tended to have too many risks for darker skin to be considered beneficial, new devices and protocols are becoming more centered on providing optimal treatment results to patients with a wider range of skin types.  

The Complexities o f PIH

One of the risks associated with previous medical aesthetic technologies for darker skin tones is post-inflammatory hyperpigmentation (PIH) , which occurs when the skin overproduces melanin, or disperses pigment irregularly, in response to inflammation or injury. PIH is the skin’s natural reaction or defense to inflammation, which may be the product of acne, an infection, an irritant, a burn, or a cosmetic procedure. It results in flat, discolored spots on the skin that create an uneven skin tone. PIH is a common skin concern among people with Fitzpatrick skin types IV to VI—which comprises a significant portion of the global aesthetic market. This segment of the population, which includes Latin Americans, Asians, Pacific Islanders, people of African descent, people of Middle Eastern descent, and the Indigenous peoples of North America among others , is at the highest risk of experiencing PIH. Ironically, until recently the therapies that were used to treat PIH also came with a high risk of causing PIH as a side effect of treatments that were too harsh for darker skin tones. The newest medical aesthetic technologies have diminished that risk so significantly, that most treatments are now safe for this demographic.

Aesthetic Treatments f or Darker Skin Tones

Unfortunately, many prospective clients who have darker skin tones may have received the message that medical aesthetic treatments are not safe for their skin type. However, with the right technology and a focus on this demographic in your marketing efforts, you can bring them into your clinic with the confidence that new technologies can safely and effectively meet their aesthetic goals.  

Radio Frequency Skin Resurfacing Treatments   

The latest in skin-resurfacing   involves fractional radio frequency (RF). Th is method has risen in popularity because it offers a safer solution for patients with darker skin tones. Innovations on fractional RF systems, like the  NanoFractional  RF™ technology used by Venus Viva™ MD, prove to be the safest choice for patients with a wider range of skin types. NanoFractional  RF™ utilizes needle-shaped pin tips as the electrode to deliver the RF energy and allows operator control of ablation and coagulation. Due to the highly adjustable power and pulse duration, the Venus Viva™ MD can ensure high enough energy delivery to be effective without further risking PIH.

Wrinkle Reduction

Regardless of tone, all skin is susceptible to aging. Wrinkle reduction treatments   a synergistic combination of Multi-Polar Radio Frequency (RF) and Pulsed Electro Magnetic Fields (PEMF) technologies. Safe for all skin tones, Multi-Polar RF delivers heat deep below the skin’s surface, stimulating fibroblasts for improved collagen production. Meanwhile, PEMF is proven to promote the formation of new blood vessels while inducing fibroblast proliferation via an increase in growth factor FGF-2 to support improved collagen synthesis. Advanced safety features, like Real - Time Thermal Feedback on the Venus Legacy™ , allow for greater operator control over target temperature selection, helping to further improve patient safety. The result is smoother, firmer skin with a reduced risk of PIH and optimal results for improved patient satisfaction.

Hair Removal  

Lasers have been used in medicine for decades, but their application for hair removal only took hold in the 1990s. Early lasers were typically very slow and painful, and they only worked on people with dark hair and fair skin. Today, diode laser hair removal treatments are generally seen as the safest and most effective modality for treating a wider range of Fitzpatrick skin types. Our Venus Velocity™ and  Venus Epileve™   devices use state-of-the-art diode laser technology   to penetrate each hair follicle thoroughly while also reducing the amount of energy absorbed by the melanin in the surrounding epidermis. This allows for safe hair removal without post-treatment PIH in people with darker skin tones.  

The expectation that all skin types are treated equally has become mainstream in the aesthetic industry. However, not all device technologies live up to these expectations. It’s time to do a careful audit of your products and services to make sure that your clinic offerings are safe for all skin types, and that you have a spectrum of services to offer those with darker skin. Luckily, many of the latest advancements in aesthetic devices ensure that treatments can be performed on all shades of skin, including those made by Venus Concept. Reach out to speak to one of our experts today to see how your clinic can start serving a wider 

September 9, 2026
TORONTO, September 9 th , 2026 (GLOBE NEWSWIRE) – Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer, effective as of September 7, 2026. He succeeds Rajiv De Silva, who will assume the role of Special Advisor to support a seamless leadership transition. The Board believes that Brad’s commercial leadership experience, strategic vision, and industry expertise position the Company well for its next phase of growth and value creation. Brad brings more than 20 years of leadership experience in the aesthetic industry, most recently as President & General Manager – Americas at Lumenis, and has a proven track record of driving growth globally, operational excellence, and innovation. "I am honored to be appointed Chief Executive Officer of Venus Concept and grateful for the confidence the Board has placed in me,” said Mr. Oliver. “The Company has established a strong foundation under Rajiv's leadership, and I look forward to working closely with him during the transition. Together with our employees, customers, and partners, we will remain focused on disciplined commercial execution, product innovation, profitable growth, and creating long-term value for our customers, employees, and shareholders.” “It has been a pleasure to lead Venus through a transformational time in the organization’s journey,” said Mr. De Silva. “I am grateful for the opportunity to work together with the leadership team, the Board and our partners to grow the business. We have transformed the commercial, operational and financial capabilities of the organization and built a strong foundation for the future. I remain highly confident in the Company’s strategy, pipeline and long-term growth opportunities. I look forward to supporting a smooth transition and watching Venus continue its transformation under Brad’s new leadership.” The Board expresses its gratitude to Rajiv for his leadership and ongoing commitment to the Company. As Special Advisor, Rajiv will work closely with Brad during the transition period to ensure continuity across strategic, operational, and customer-facing initiatives. “On behalf of the Board, I would like to thank Rajiv for his leadership and contributions to the Company and for his support during this transition to ensure a seamless handoff of leadership responsibilities,” said Avinash Amin, M.D., Managing Partner of Madryn Asset Management and Chairman of the Board. “The Board looks forward to Brad’s new leadership of the organization and is confident that his expertise will accelerate commercial efforts globally and the execution of its strategic priorities as the company progresses towards continuing to establish a leadership position in the Medical Device Aesthetics industry.” The leadership transition is not expected to impact the Company’s strategic priorities, customer relationships, employee commitments, or ongoing business operations. Venus Concept remains focused on delivering innovative solutions to its customers, expanding market opportunities, and driving sustainable long-term growth. About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft ® and the ARTAS iX ® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. View Full Article Investor Relations Contact : Damian Yeung, CPA investorrelations@venus.ai
Purple gradient branding graphic for Doublo × Venus Signature Edition
July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.